292 related articles for article (PubMed ID: 9249034)
1. Plasminogen activation by pro-urokinase in complex with its receptor--dependence on a tripeptide (Spectrozyme plasmin).
Wang J; Mazar A; Quan N; Schneider A; Henkin J
Eur J Biochem; 1997 Jul; 247(1):256-61. PubMed ID: 9249034
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
Petersen LC
Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
[TBL] [Abstract][Full Text] [Related]
3. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
Ellis V
J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
[TBL] [Abstract][Full Text] [Related]
4. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
[TBL] [Abstract][Full Text] [Related]
5. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
6. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.
Stepanova V; Mukhina S; Köhler E; Resink TJ; Erne P; Tkachuk VA
Mol Cell Biochem; 1999 May; 195(1-2):199-206. PubMed ID: 10395084
[TBL] [Abstract][Full Text] [Related]
7. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
8. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities.
Husain SS
Biochemistry; 1991 Jun; 30(23):5797-805. PubMed ID: 1828371
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of receptor-bound pro-urokinase-type plasminogen activator (pro-uPA) by thrombin and thrombin/thrombomodulin complex.
Wilhelm S; Wilhelm O; Schmitt M; Graeff H
Biol Chem Hoppe Seyler; 1994 Sep; 375(9):603-8. PubMed ID: 7840902
[TBL] [Abstract][Full Text] [Related]
10. Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87).
Longstaff C; Merton RE; Fabregas P; Felez J
Blood; 1999 Jun; 93(11):3839-46. PubMed ID: 10339491
[TBL] [Abstract][Full Text] [Related]
11. Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA).
Baker MS; Liang XM; Doe WF
Biochim Biophys Acta; 1992 Sep; 1117(2):143-52. PubMed ID: 1381963
[TBL] [Abstract][Full Text] [Related]
12. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
Behrendt N; List K; Andreasen PA; Danø K
Biochem J; 2003 Apr; 371(Pt 2):277-87. PubMed ID: 12534347
[TBL] [Abstract][Full Text] [Related]
13. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system.
Behrendt N; Danø K
FEBS Lett; 1996 Sep; 393(1):31-6. PubMed ID: 8804418
[TBL] [Abstract][Full Text] [Related]
14. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen.
Ellis V; Whawell SA; Werner F; Deadman JJ
Biochemistry; 1999 Jan; 38(2):651-9. PubMed ID: 9888805
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
16. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
[TBL] [Abstract][Full Text] [Related]
18. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
19. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
20. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
